1-10 of 10
Jesse J. Smith
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

Free
Dorothy Brach, Danielle Johnston-Blackwell, Allison Drew, Trupti Lingaraj, Vinny Motwani, Natalie M. Warholic, Igor Feldman, Christopher Plescia, Jesse J. Smith, Robert A. Copeland, Heike Keilhack, Elayne Chan-Penebre, Sarah K. Knutson, Scott A. Ribich, Alejandra Raimondi, Michael J. Thomenius
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (11): 2586–2597.
https://doi.org/10.1158/1535-7163.MCT-16-0840
Published: 01 November 2017
View articletitled, EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
Open the PDF for EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL in another window
Includes: Supplementary data
Journal Articles

Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL-Rearranged Leukemia

Free
Carly T. Campbell, Jessica N. Haladyna, David A. Drubin, Ty M. Thomson, Michael J. Maria, Taylor Yamauchi, Nigel J. Waters, Edward J. Olhava, Roy M. Pollock, Jesse J. Smith, Robert A. Copeland, Stephen J. Blakemore, Kathrin M. Bernt, Scott R. Daigle
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (8): 1669–1679.
https://doi.org/10.1158/1535-7163.MCT-16-0693
Published: 02 August 2017
View articletitled, Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL-Rearranged Leukemia
Open the PDF for Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL-Rearranged Leukemia in another window
Includes: Supplementary data
Journal Articles

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models

Free
Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R. Grassian, Igor Feldman, Sarah K. Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A. Copeland, Richard Chesworth, Jesse J. Smith, Heike Keilhack, Scott A. Ribich
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (5): 850–860.
https://doi.org/10.1158/1535-7163.MCT-16-0678
Published: 02 May 2017
View articletitled, Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
Open the PDF for Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Abstract B78: CRISPR pooled screening identifies differential dependencies on epigenetic pathways

Free
Alexandra R. Grassian, Julian Fowler, Igor Feldman, Thomas Riera, Darren Harvey, Allison E. Drew, Richard Chesworth, Robert A. Copeland, Heike Keilhack, Jesse J. Smith, Scott Ribich
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B78.
https://doi.org/10.1158/1535-7163.TARG-15-B78
Published: 01 December 2015
View articletitled, Abstract B78: CRISPR pooled screening identifies differential dependencies on epigenetic pathways
Journal Articles

Abstract C87: EZH2 inhibition leads to decreased proliferation in SMARCA4-deleted ovarian cancer cell lines

Free
Sarah K. Knutson, Allison E. Drew, Christopher Plescia, Robert A. Copeland, Jesse J. Smith, Heike Keilhack, Scott Ribich
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C87.
https://doi.org/10.1158/1535-7163.TARG-15-C87
Published: 01 December 2015
View articletitled, Abstract C87: EZH2 inhibition leads to decreased proliferation in SMARCA4-deleted ovarian cancer cell lines
Journal Articles

Abstract C85: Identification of a novel potent selective SMYD3 inhibitor with oral bioavailability

Free
Lorna H. Mitchell, Paula A. Boriack-Sjodin, Sherri Smith, Michael Thomenius, Nathalie Rioux, Michael Munchhof, James E. Mills, Christine Klaus, Jennifer Totman, Thomas V. Riera, Alejandra Raimondi, Suzanne L. Jacques, Megan Foley, Nigel J. Waters, Kevin W. Kuntz, Tim J. Wigle, Margaret Porter Scott, Robert A. Copeland, Jesse J. Smith, Richard Chesworth
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C85.
https://doi.org/10.1158/1535-7163.TARG-15-C85
Published: 01 December 2015
View articletitled, Abstract C85: Identification of a novel potent selective SMYD3 inhibitor with oral bioavailability
Journal Articles

Abstract B85: EZH2 plays a critical role in B-cell maturation and in non-Hodgkin's lymphoma: Interplay between EZH2 function and B-cell activation

Free
Danielle Johnston, Dorothy Brach, Christopher Plescia, Alison Drew, Trupti Lingaraj, Natalie Warholic, Jesse J. Smith, Robert A. Copeland, Heike Keilhack, Elayne Penebre, Sarah K. Knutson, Scott Ribich, Michael J. Thomenius, Alejandra Raimondi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B85.
https://doi.org/10.1158/1535-7163.TARG-15-B85
Published: 01 December 2015
View articletitled, Abstract B85: EZH2 plays a critical role in B-cell maturation and in non-Hodgkin's lymphoma: Interplay between EZH2 function and B-cell activation
Journal Articles

Abstract B82: Pinometostat (EPZ-5676) enhances the antiproliferative activity of MAP kinase pathway inhibitors in MLL-rearranged leukemia cell lines

Free
Alejandra Raimondi, Christine R. Klaus, Jeffrey A. Keats, Scott R. Daigle, Robert A. Copeland, Jorge DiMartino, Jesse J. Smith, Stephen J. Blakemore
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B82.
https://doi.org/10.1158/1535-7163.TARG-15-B82
Published: 01 December 2015
View articletitled, Abstract B82: Pinometostat (EPZ-5676) enhances the antiproliferative activity of MAP kinase pathway inhibitors in MLL-rearranged leukemia cell lines
Journal Articles

Abstract C162: A medium-throughput single cell CRISPR-Cas9 assay to assess gene essentiality

Free
Alexandra R. Grassian, Tim Scales, Sarah K. Knutson, Nicola J. McCarthy, Chris E. Lowe, Jon D. Moore, Robert A. Copeland, Heike Keilhack, Jesse J. Smith, Julie A. Wickendon, Scott Ribich
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C162.
https://doi.org/10.1158/1535-7163.TARG-15-C162
Published: 01 December 2015
View articletitled, Abstract C162: A medium-throughput single cell CRISPR-Cas9 assay to assess gene essentiality
Journal Articles

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

Free
Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima, Natalie M. Warholic, Kuan-Chun Huang, Yonghong Xiao, Tadashi Kadowaki, Mai Uesugi, Galina Kuznetsov, Namita Kumar, Tim J. Wigle, Christine R. Klaus, Christina J. Allain, Alejandra Raimondi, Nigel J. Waters, Jesse J. Smith, Margaret Porter-Scott, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Toshimitsu Uenaka, Roy M. Pollock, Kevin W. Kuntz, Akira Yokoi, Heike Keilhack
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (4): 842–854.
https://doi.org/10.1158/1535-7163.MCT-13-0773
Published: 06 April 2014
View articletitled, Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Open the PDF for Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma in another window
Includes: Supplementary data